贝伐珠单抗靶向治疗转移性结肠癌患者的临床研究

Bevacizumab targeted therapy in metastatic colon cancer

目的探讨贝伐珠单抗联合FOLFOX-6化疗方案治疗转移性结肠癌患者的临床效果。方法选取行化疗的转移性结肠癌患者84例进行本次临床研究,其中研究组（n=30）采用贝伐珠单抗注射液联合FOLFOX-6治疗,对照组（n=54）采用单纯FOLFOX-6化疗方案治疗,隔14d治疗1次,连续治疗3-5次。对比2组患者的临床疗效及远期预后。结果研究组的缓解率46.67%、总有效率86.67%均显著高于对照组的14.81%、62.96%,差异均具有统计学意义（P〈0.05）;研究组的无进展生存期（progression-free survival,PFS）7.0个月、总生存期（overall survival,OS）21.0个月均显著长于对照组的4.0、15.0个月,差异均具有统计学意义（P〈0.05）;研究组24个月存活18例、失访2例,对照组24个月存活24例,失访3例,研究组的存活率与对照组比较差异无统计学意义（60.00%vs.44.44%,χ2=1.867）。结论贝伐珠单抗联合FOLFOX-6化疗方案治疗转移性结肠癌具有较好的临床效果及安全性。

Objective To explore the clinical effect of bevacizumab combined with FOLFOX-6 chemotherapy in the treatment of patients with metastatic colon cancer. Methods 84 patients with metastatic colon cancer who received chemotherapy and were divided into study group of 30 patients received bevacizumab injection combined with FOLFOX-6,and control group of 54 patients received FOLFOX-6 chemotherapy. The curative effect and long-term prognosis between the two groups were compared. Results The remission rate（46. 67%） and the total effective rate（86. 67%） in the study group were significantly higher than those in the control group（14. 81%,62. 96%）,the differences were statistically significant（P〈0. 05）; The progression-free survival（PFS）（7. 0 months） and the overall survival（OS）（21. 0 months） in the study group were significantly longer than that（4. 0months,15. 0 months） in the control group,the differences were statistically significant（P〈0. 05）. In the study group,the survival time of 18 patients was longer than 24 months,2 patients lost of follow-up. In the control group,the survival time of 24 patients was longer than 24 months,3 patients lost of follow-up; there was no significant difference in survival rate between study group and control group（60. 00% vs. 44. 44%）,but the difference was not statistically significant（χ2= 1. 867）. Conclusion Bevacizumab combined with FOLFOX-6 chemotherapy in the treatment of metastatic colon cancer has good clinical effect and safety.